MYD88 mutations are associated with worse clinical outcomes compared to non-mutated DLBCL, which is frequently associated with extranodal involvement, advanced age (thus a high IPI), and a non-GCB subtype [12, 13]. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.